BlackRock
EYEGW

BlackRock’s Eyegate Pharmaceuticals, Inc. Warrants EYEGW Stock Holding History

BlackRock’s Portfolio EYEGW Stock Details EYEGW Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-46,688
Closed -$7K – 5133
2017
Q1 		$7K Buy
+46,688
New +$11.2K ﹤0.01% 4759

Other funds holding EYEGW

AIC
AWM Investment Company New York $903M AUM 163.47% 1-Year Est. Return
VKH
Virtu KCG Holdings New York $3.6B AUM 17.11% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return

BlackRock's EYEGW Position: Q2 2017 in Review

BlackRock sold out of Eyegate Pharmaceuticals, Inc. Warrants (EYEGW) in Q2 2017, closing a stake of 46,688 shares — an estimated $7K sold.

BlackRock first reported a position in EYEGW in Q1 2017 and held it in 1 quarter. The position peaked at $7K in Q1 2017. 4 funds tracked by Wall St. Rank hold EYEGW as of Q2 2017.

  • BlackRock reported no remaining Eyegate Pharmaceuticals, Inc. Warrants position as of Q2 2017 after selling out during the quarter.
  • BlackRock sold 46,688 Eyegate Pharmaceuticals, Inc. Warrants shares in Q2 2017, an estimated $7K.
  • BlackRock first reported a position in Eyegate Pharmaceuticals, Inc. Warrants in Q1 2017 and held it in 1 quarter.
  • BlackRock's Eyegate Pharmaceuticals, Inc. Warrants position peaked at $7K in Q1 2017.
  • 4 funds tracked by Wall St. Rank held Eyegate Pharmaceuticals, Inc. Warrants as of Q2 2017.

Based on BlackRock's 13F filing for Q2 2017, filed 10 Aug 2017.